Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant700 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,395 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03422029 | Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | unknown | Phase 2 | 20 | Peking UniversityOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03613597 | Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer | unknown | Phase 2 | 118 | Guizhou Medical UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03613753 |
| Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer |
| unknown |
| Phase 2 |
| 72 |
| ShengFa SuOTHER |
| 1 |
| Feb 5, 2020 |
| clinicaltrials |
| NCT04254471 | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | unknown | Phase 2 / Phase 3 | 313 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | completed | Phase 2 | 9 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04192682 | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01880528 | Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer | completed | Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT03147404 | Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes(MS100070-0177) | completed | Phase 2 | 14 | Samsung Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04213937 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 386 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02248012 | Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) | completed | Phase 2 | 38 | Haukeland University HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT01913691 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00985946 | Study of Panobinostat in Patients With Neuroendocrine Tumors | terminated | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT03700359 | A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC | unknown | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00501540 | Lithium for Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00388960 | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 99 | CelgeneINDUSTRY | 5 | Nov 19, 2019 | clinicaltrials |
| NCT00537511 | A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide | terminated | Phase 1 / Phase 2 | 22 | CelgeneINDUSTRY | 2 | Nov 19, 2019 | clinicaltrials |
| NCT01967537 | Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors | completed | Phase 2 | 341 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | completed | Phase 2 | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | withdrawn | Phase 1 / Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04128800 | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01456078 | A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors(ILUMINET) | completed | Phase 2 | 60 | Lund University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT00781911 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | completed | Phase 2 | 14 | Gabrail Cancer Center ResearchOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | unknown | Phase 2 | 68 | Hunan Cancer HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT04056949 | Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy | unknown | Phase 2 | 30 | Junling LiOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations | terminated | Phase 2 | 18 | Clovis Oncology, Inc.INDUSTRY | 5 | Jul 29, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03992911 | Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma | unknown | Phase 2 / Phase 3 | 336 | Peking UniversityOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT01280201 | Pazopanib as Single Agent in Advanced NETs | completed | Phase 2 | 44 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03963193 | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type | unknown | Phase 2 | 112 | Henan Cancer HospitalOTHER_GOV | 0 | May 24, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT01283542 | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.(Passion I) | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02457273 | Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients | completed | Phase 2 | 23 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 3, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2020source: clinicaltrials